Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.

被引：7
|
作者：
Cheng, Ke
Lv, Wan-Rui
Li, Xiaofen
Tian, Bole
Cao, Dan
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Oncol, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16213
引用
收藏
页数：3
相关论文
共 50 条
  • [31] PanCO: An Open-Label, Single-Arm Pilot Study of Phosphorus-32 Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma with FOLFIRINOX or Gemcitabine plus Nab-Paclitaxel Chemotherapies
    Ross, Paul
    Phillips, Natalie
    Win, Zarni
    Wadsworth, Christopher
    Ajithkumar, Thankamma
    Aloj, Luigi
    Godfrey, Edmund
    Iwuji, Chinenye
    Ganatra, Rakesh
    Kadri, Sudarshan
    Harris, Marion
    Croagh, Daniel
    Aghmesheh, Morteza
    Nagrial, Adnan
    Nam Nguyen
    Nikfarjam, Mehrdad
    Hendlisz, Alain
    Maher, Thomas
    Kraszewski, Anna
    Wasan, Harpreet
    BRITISH JOURNAL OF CANCER, 2019, 121 : 23 - 24
  • [32] Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2019, 37 : 797 - 797
  • [33] Gemcitabine plus nab-paclitaxel for second-line therapy of pancreatic cancer: A phase II, single-arm, multicenter study
    Huh, Gunn
    Choi, Jin Ho
    Lee, Sang Hyub
    Chun, Jung Won
    Cho, In Rae
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Lee, Hee Seung
    Bang, Seungmin
    ANNALS OF ONCOLOGY, 2021, 32 : S287 - S287
  • [34] A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
    Pelzer, Uwe
    Bendell, Johanna C.
    Womack, Mark S.
    Bahary, Nathan
    Macarulla, Teresa
    Borazanci, Erkut Hasan
    Levy, Donna Elise
    Mo, Gary
    Ramage, Samuel Cowan
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [35] Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
    Wen Zhang
    Chunxia Du
    Yongkun Sun
    Lin Yang
    Chengxu Cui
    Zhichao Jiang
    Chengfeng Wang
    Jinwang Wang
    Aiping Zhou
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 655 - 660
  • [36] Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward J.
    George, Ben
    Kaylan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David M.
    Guiterrez, Martin
    Parikh, Aparna
    Jain, Rishi
    Carrizosa, Daniel Ricardo
    Soliman, Hatem H.
    Lila, Thomas
    Reiss, David J.
    Pierce, Daniel W.
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal U.
    Ong, Teng Jin
    O'Dwyer, Peter J.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4814 - 4822
  • [37] Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
    Zhang, Wen
    Du, Chunxia
    Sun, Yongkun
    Yang, Lin
    Cui, Chengxu
    Jiang, Zhichao
    Wang, Chengfeng
    Wang, Jinwang
    Zhou, Aiping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 655 - 660
  • [38] Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol
    Zhang, Chenyan
    Yang, Heqi
    Chang, Chen
    Li, Ruizhen
    Xiong, Junjie
    Kang, Deying
    He, Du
    Liu, Xi-Jiao
    Cheng, Ke
    Cao, Dan
    BMJ OPEN, 2024, 14 (07): : 1 - 8
  • [39] A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
    Li, G.
    Zhao, Y.
    Jiang, Y.
    Yang, Q.
    Huang, A.
    Chen, Y.
    Han, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S753 - S754
  • [40] Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma A Phase 2 Clinical Trial
    Sahai, Vaibhav
    Catalano, Paul J.
    Zalupski, Mark M.
    Lubner, Sam Joseph
    Menge, Mark R.
    Nimeiri, Halla Sayed
    Munshi, Hidayatullah G.
    Benson, Al Bowen, III
    O'Dwyer, Peter J.
    JAMA ONCOLOGY, 2018, 4 (12) : 1707 - 1712
12345